Key Takeaway: Indivior PLC has concluded its legacy matter with the U.S. Department of Justice by paying $295 million. This payment, made from the company's cash reserves, terminates the resolution agreement with the DOJ. CEO Joe Ciaffoni expressed satisfaction with this milestone, highlighting its positive impact on the company's liability and capital structure.
Price reaction · baseline $31.77 (2025-11-20 close) · hit after-hours · clean, no other INDV news in the window
day 0 close · peak
+3.1%
Market Sentiment Analysis
POSITIVE FACTORS
Indivior has successfully resolved a significant legal matter.
The payment simplifies the company's capital structure.
The resolution allows Indivior to focus on its core mission.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
5.4%
average across 2 past catalysts
Lead asset
RBP-6000
Phase 3 · Opioid Use Disorder
Full Press Release Details
RICHMOND, Va.,Nov. 20, 2025/PRNewswire/ -- Indivior PLC (Nasdaq:INDV) today announced the Company has concluded the legacy U.S. Department of Justice (DOJ) matter by paying in full the outstanding obligation of $295 million associated with the matter. With the DOJ's receipt of the payment, the resolution agreement with the DOJ will be terminated. The payment was funded with Indivior's cash on hand.
"We are pleased to reach this important milestone that concludes the legacy DOJ matter," said Joe Ciaffoni, Chief Executive Officer. "It removes a significant liability and simplifies our capital structure. We are committed to conducting business with integrity, maintaining a comprehensive compliance program and acting in a responsible and transparent manner."
About Indivior
Indivior works to help change patients' lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a human crisis to a recognized and treated chronic disease. Building on its portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Visitwww.indivior.comto learn more. Connect with Indivior on LinkedIn by visitingwww.linkedin.com/company/Indivior.
Frequently Asked Questions
What was the amount paid to the DOJ by Indivior?
Indivior paid $295 million to resolve the legacy DOJ matter.
How did Indivior fund the DOJ payment?
The payment was funded using Indivior's cash on hand.
What does the resolution of the DOJ matter mean for Indivior?
It removes a significant liability and simplifies the company's capital structure.
Who is the CEO of Indivior?
Joe Ciaffoni is the Chief Executive Officer of Indivior.